# A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

> **NCT04755244** · PHASE1 · TERMINATED · sponsor: **ALX Oncology Inc.** · enrollment: 14 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- AML, Adult

## Interventions

- **DRUG:** evorpacept
- **DRUG:** venetoclax
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT04755244
- **Lead sponsor:** ALX Oncology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-05
- **Primary completion:** 2023-05-05
- **Final completion:** 2023-08-16
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2.
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04755244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04755244, "A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04755244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*